



Attorney Docket No. 03327.2337-00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 7,183,271	)
Inventors: KOSHIO et al.	)
Issue Date.: February 27, 2007	) Cellilicale )
For: 4,4-DIFLUORO-1,2,3,4- TETRAHYDRO-5H-1- BENZAZEPINE DERIVATIVES OR SALTS THEREOF	) PEB 0 1 2008

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. § 255, and 37 C.F.R. § 1.323, this is a request for a Certificate of Correction in the above-identified patent. The mistake(s) identified in the appended Form are of a clerical or typographical nature, or of minor character, and resulted from an error made in good faith by patentee(s). A check in the amount of \$100 (the fee set forth in 37 C.F.R. § 1.20(a)) is attached. Should a check not be appended or should any additional fees be needed, authorization is hereby given to charge any fees due in connection with the filling of this request to Deposit Account 06-0916.

Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves one (1) page. Issuance of the Certificate of Correction containing the correction is earnestly requested.

01/31/2008 AWONDAF1 00000108 7183271 100.00 OP

01 FC:1811

Please charge any required fees not included herewith to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: January 30, 2008

Jessica H. Roark Reg. No. 54,869

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

7,183,271

Page 1 of 1

**APPLICATION NO.:** 

10/544,150

**ISSUE DATE:** 

February 27, 2007

INVENTOR(S):

KOSHIO et al.

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 8, line 25, "cycloalkenyl" should read -- cycloalkyl --.

Claim 9, col. 61, lines 20-22,

"(2Z)-2-{4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,"

should read

 $--(2Z)-2-\{4,4-difluoro-1-[4-\{[(2S)-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy}-2-fluoropropyl$ 

(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,--.

Claim 9, col. 61, lines 23-25,

(2Z)-2-{4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-

[(2R)-2,3-dihydroxypropyl]acetamide,"

should read

 $--(2Z)-2-\{4,4-difluoro-1-[4-\{[(2R)-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy}-2-fluoropropyl$ 

(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide,--.

Claim 9, col. 62, line 6. "[4-{](2S)-2-" should read -- [4-{[(2S)-2---.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 901 New York Avenue, N.W. Washington, D.C. 20001-4413

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

7,183,271

Page 1 of 1

**APPLICATION NO.:** 

10/544,150

**ISSUE DATE:** 

February 27, 2007

INVENTOR(S):

KOSHIO et al.

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 8, line 25, "cycloalkenyl" should read -- cycloalkyl --.

Claim 9, col. 61, lines 20-22,

"(2Z)-2-{4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,"

should read

 $--(2Z)-2-\{4,4-difluoro-1-[4-\{[(2S)-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy}-2-fluoropropyl$ 

(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,--.

Claim 9, col. 61, lines 23-25,

(2Z)-2-{4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-

[(2R)-2,3-dihydroxypropyl]acetamide,"

should read

 $--(2Z)-2-\{4,4-difluoro-1-[4-\{[(2R)-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy\}-2-fluoropropyl]oxy}-2-fluoropropyl$ 

(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide,--.

Claim 9, col. 62, line 6. "[4-{](2S)-2-" should read -- [4-{[(2S)-2---.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 901 New York Avenue, N.W. Washington, D.C. 20001-4413